Unexpected Pharmacokinetics of Vancomycin in Patients With Severe Acute Pancreatitis Compared With Pneumonia

Shanghai Jiao Tong University

Status: Unknown

Conditions: Arbitrary Restriction Polymorphism 1

Study type: Observational

Funder types: Other

Identifiers

NCT02134665

hejuanwin19811119

Details and patient eligibility

About

The purpose of this study was to evaluate the influence of severe acute pancreatitis on the serum level of vancomycin, a glycopeptide antibacterial agent.

Full description

The purpose of this study was to evaluate the influence of severe acute pancreatitis on the serum level of vancomycin, a glycopeptide antibacterial agent.

After reviewing more than 6000 clinical charts of patients who received vancomycin therapy and whose serum vancomycin level was monitored between January 2010 and December 2013, we identified 212 patients who also had diagnosed as severe acute pancreatitis (SAP group), and 98 patients who also had diagnosed as pneumonia (pneumonia group) at that time. The fluorescence polarization immunoassay method was used to measure vancomycin serum trough concentrations in these patients 30 min before the next administration. Using these measurements, we calculated the pharmacokinetic parameters using the Bayesian estimator.

Enrollment: 200 estimated patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age 18-85years old
• vancomycin use ≥ 3days

Exclusion criteria

• age <18years old or >85 years old
• vancomycin use < 3days

Trial design

200 participants in 2 patient groups

severe acute pancreatitis

Description:

patients who received vancomycin therapy and whose serum vancomycin level was monitored, and who also had diagnosed as severe acute pancreatitis.

Pneumonia

Description:

patients who received vancomycin therapy and whose serum vancomycin level was monitored, and who also had diagnosed as pneumonia.